title: Clozapine-associated extrapyramidal reaction.
abstract: OBJECTIVE
  To report a case of extrapyramidal reaction associated with a dosage increase of clozapine.
  
  
  METHODS
  A 44-year-old white man with a 20-year history of chronic paranoid schizophrenia was admitted to an inpatient psychiatric facility. His prior medications restarted on admission were clozapine 650 mg at bedtime, haloperidol 10 mg at bedtime, clonazepam 2 mg/d, and aspirin 325 mg/d. Two days after admission (hospital day 3), clozapine and clonazepam were discontinued, and he was prescribed haloperidol 5 mg every morning and 10 mg every evening. Stabilization occurred over the following 24 days, with progressively lower dosages of haloperidol and increasing dosages of clozapine. Haloperidol was discontinued on day 24. On day 47, the patient was agitated and making bizarre statements; thus, the morning dose of clozapine was increased by 50 mg (total 450 mg/d). On day 48 at 2200, a dystonic reaction was diagnosed; he received intramuscular diphenhydramine 50 mg, which caused the reaction to subside. At the time of the adverse reaction, he was prescribed clozapine 450 mg/d, vitamin E 400 IU three times daily, aspirin 325 mg/d, and acetaminophen, milk of magnesia, and Maalox as needed.
  
  
  CONCLUSIONS
  Although the risk of extrapyramidal symptoms (EPS) is significantly lower with clozapine than with conventional agents, elevated clozapine blood concentrations have been reported to cause EPS; other reports have cited severe dystonias and dyskinesias on abrupt clozapine withdrawal. Considering the medications prescribed at the time and the discontinuation of haloperidol 24 days before the event, clozapine was the most likely cause of the extrapyramidal reaction.
  
  
  CONCLUSIONS
  Regardless of anticipated safety associated with novel antipsychotics such as clozapine, reports of dystonic reactions must be taken into account and patients monitored appropriately.
authors.affiliation: Pharmacy Practice Resident, Western Missouri Mental Health Center, Kansas City, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Elliott
authors.forename: P A
authors.initials: PA
authors.lastname: Marken
authors.forename: V L
authors.initials: VL
authors.lastname: Ruehter
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000503:physiopathology; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects*; D020820:Dyskinesias / Q000150:complications / Q000188:drug therapy; D004421:Dystonia / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine